D-0021-2025 Class II Terminated
FDA drug recall D-0021-2025 was initiated by Fresenius Kabi Compounding, LLC on Sep 25, 2024 and is designated Class II. Reason for recall: cGMP violations The recall status is terminated (terminated Aug 15, 2025). Affected quantity: 4436 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 30, 2024
- Initiation Date
- Sep 25, 2024
- Termination Date
- Aug 15, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4436 bags
Product description
Oxytocin 0.9% Sodium Chloride Injection USP, 30 units per 500 mL Single Dose Bag, Rx only, Fagron Sterile Services, Canton, MA NDC: 71506-028-59
Reason for recall
cGMP violations
Distribution pattern
Product was distributed to 125 direct accounts nationwide.
Code information
Lot # C274-000038801, exp. date 9-Oct-24 C274-000039045, exp. date 24-Oct-24 C274-000039240, exp. date 31-Oct-24
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0021-2025
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026